Clinical Takeda Pharmaceutical gets FDA nod for lung cancer drug...

Takeda Pharmaceutical gets FDA nod for lung cancer drug Exkivity


The U.S. Food and Drug Administration had approved Takeda Pharmaceutical Co.’s drug, Exkivity, to treat a particular type of lung cancer, the Japanese pharmaceutical company announced on 15th September.

The drug has been approved only for patients having a particular gene mutation in non-small cell lung cancer (NSCLC) known as EGFR Exon 20 insertion, whose disease has grown during or after the chemotherapy.   

Exkivity’s approval from the FDA was explicitly based on some affirmative and meaningful results yielded from early-to-mid stage trials carried out on 114 patients having NSCLC, over a period of 18 months on average, the company said, which is subjected to the verification and description of clinical benefit through confirmatory trials.

However, the drug is marketed with a boxed warning indicating potential risks relating to the heart toxicity, heart rhythm disturbance and lung diseases.

According to the World Health Organization, NSCLC is the most common type of lung cancer constituting up to 85% of the estimated 2.2 million cases of lung cancer diagnosed every year globally.   

+ posts

Latest news

Novo Nordisk Set to Slash Victoza Production to Boost Ozempic Supply

In response to the escalating demand for its GLP-1 weight loss products, Novo Nordisk is adopting a...

Merck to Purchase Caraway Therapeutics For Over $600M

Merck & Co. has openly expressed its continuous pursuit of acquisitions, and currently, the prominent pharmaceutical company...

NanoString Faces Setback in Patent Infringement Case Against Genomics

In a recent legal skirmish in the biotechnology sector, NanoString finds itself on the losing end of...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you